Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director · Executive Chair | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,214 |
Last balance in matching sequence
After 2026-08-20 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-08-20 · Sale · Disposed 19,308 · Balance 309,662 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 2 · 2026-08-20 · Sale · Disposed 7,351 · Balance 302,311 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 3 · 2026-08-20 · Sale · Disposed 97 · Balance 302,214 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 24, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 97 | $91.41 | $8,866.77 |
DisclosureSEC source: 0001093557-26-000151 · wk-form4_1787601701.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,214 F1 · shares: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F3 · balance_after: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,351 | $90.78 | $667,331.87 |
DisclosureSEC source: 0001093557-26-000151 · wk-form4_1787601701.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,311 F1 · shares: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 19,308 | $89.71 | $1,732,043.45 |
DisclosureSEC source: 0001093557-26-000151 · wk-form4_1787601701.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,662 F1 · shares: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 20:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 26,756 | $76.32 | $2,041,999.19 |
DisclosureSEC source: 0001093557-26-000137 · wk-form4_1784667520.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 328,970 F1 · shares: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.80 to $76.62. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 20:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 26,756 | $72.00 | $1,926,432.00 |
DisclosureSEC source: 0001093557-26-000133 · wk-form4_1783454979.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 355,726 F1 · shares: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 · balance_after: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 26,759 | $72.00 | $1,926,648.00 |
DisclosureSEC source: 0001093557-26-000089 · wk-form4_1779826702.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,482 F1 · shares: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2 · balance_after: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 20:02 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 32,498 | $68.10 | $2,213,113.80 |
DisclosureSEC source: 0001093557-26-000050 · wk-form4_1773172919.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,241 F2 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F3 · balance_after: Included in this number are 106,972 unvested RSUs, 32,749 of which were granted on March 8, 2026 and shall vest on March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 20:02 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 32,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000050 · wk-form4_1773172919.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,739 F1 · shares: Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting on the one year anniversary of the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | Tax withholdingCommon Stock | 34,257 | $73.36 | $2,513,093.52 |
DisclosureSEC source: 0001093557-26-000009 · wk-form4_1770068780.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,990 F2 · shares: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of PSUs and does not represent a sale by the Reporting Person. F3 · balance_after: Included in this number are 138,091 unvested restricted stock units, 85,490 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 34,461 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 18,140 of which were granted on March 9, 2023 and shall vest through March 8, 2026. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 71,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000009 · wk-form4_1770068780.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,247 F1 · shares: Represents shares issued to the Reporting Person upon vesting of performance-based restricted stock units (PSUs) granted to the Reporting Person on March 9, 2023, resulting from achievement of performance conditions under the PSUs. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:24 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 32,498 | $70.38 | $2,287,212.49 |
DisclosureSEC source: 0001093557-25-000077 · wk-form4_1741987489.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,029 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 138,091 unvested restricted stock units, 85,490 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 34,461 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 18,140 of which were granted on March 9, 2023 and shall vest through March 8, 2026. Read SEC document |
| March 08, 2025 Filed Mar 11, 2025 23:17 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 85,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000066 · wk-form4_1741735060.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,527 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 138,091 unvested restricted stock units, 85,490 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 34,461 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 18,140 of which were granted on March 9, 2023 and shall vest through March 8, 2026. Read SEC document |
| January 29, 2025 Filed Jan 30, 2025 23:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 33,359 | $86.91 | $2,899,367.46 |
DisclosureSEC source: 0001093557-25-000015 · wk-form4_1738280630.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,037 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, and 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 23:43 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 68,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000015 · wk-form4_1738280630.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,396 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025. F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, and 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 20:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 22,361 | $138.71 | $3,101,647.35 |
DisclosureSEC source: 0001093557-24-000062 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,893 F1 · shares: On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $138.385 to $139.15. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 20:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 27,272 | $137.96 | $3,762,488.76 |
DisclosureSEC source: 0001093557-24-000062 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,254 F1 · shares: On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $137.61 to $138.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,939 | $134.07 | $394,022.62 |
DisclosureSEC source: 0001093557-24-000052 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 333,526 F3 · shares: On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $134.05 to $134.12. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 20,930 | $133.55 | $2,795,144.99 |
DisclosureSEC source: 0001093557-24-000052 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,465 F3 · shares: On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $133.00 to $133.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 14,993 | $132.43 | $1,985,570.97 |
DisclosureSEC source: 0001093557-24-000052 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 357,395 F3 · shares: On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $131.90 to $132.88. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 12,470 | $131.47 | $1,639,427.16 |
DisclosureSEC source: 0001093557-24-000052 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 372,388 F3 · shares: On December 12, 2023, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $130.89 to $131.84. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 29,675 | $134.41 | $3,988,637.52 |
DisclosureSEC source: 0001093557-24-000052 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 384,858 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:31 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 51,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000038 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,533 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025. Read SEC document |
| January 16, 2024 Filed Jan 17, 2024 23:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 37,325 | $123.63 | $4,614,668.91 |
DisclosureSEC source: 0001093557-24-000012 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,841 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 23:49 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 72,709 | $0.00 | $72.71 |
DisclosureSEC source: 0001093557-24-000012 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President, CEO and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,166 F1 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024. F1 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2021 that vested on January 12, 2024. F2 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 9, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,599 | $115.70 | $416,390.98 |
DisclosureSEC source: 0001093557-23-000096 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,457 F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F5 · price: This transaction was executed in multiple trades at prices ranging from $115.435 to $116.03. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 11,218 | $114.39 | $1,283,255.07 |
DisclosureSEC source: 0001093557-23-000096 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,056 F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.065 to $115.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,995 | $113.83 | $682,422.84 |
DisclosureSEC source: 0001093557-23-000096 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,274 F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $113.33 to $114.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:47 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 11,047 | $111.40 | $1,230,624.75 |
DisclosureSEC source: 0001093557-23-000082 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,269 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:47 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 9,141 | $111.40 | $1,018,298.26 |
DisclosureSEC source: 0001093557-23-000082 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,316 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:47 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 17,302 | $111.40 | $1,927,425.50 |
DisclosureSEC source: 0001093557-23-000082 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,457 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 21:01 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 54,422 | $0.00 | $54.42 |
DisclosureSEC source: 0001093557-23-000058 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,759 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,261 | $110.41 | $801,704.44 |
DisclosureSEC source: 0001093557-23-000030 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,337 F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $110.31 to $110.51. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 31,203 | $109.83 | $3,426,906.92 |
DisclosureSEC source: 0001093557-23-000030 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,598 F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $109.41 to $110.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 9,151 | $106.65 | $975,975.20 |
DisclosureSEC source: 0001093557-23-000015 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,801 F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $106.50 to $106.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 47,693 | $106.06 | $5,058,147.89 |
DisclosureSEC source: 0001093557-23-000015 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,952 F1 · shares: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $105.521 to $106.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:17 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 45,607 | $105.75 | $4,822,871.84 |
DisclosureSEC source: 0001093557-23-000012 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,645 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 23:10 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 90,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-23-000008 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,252 F3 · kind: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2020 that vested on January 18, 2023, with the applicable performance achieved. F3 · shares: Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2020 that vested on January 18, 2023, with the applicable performance achieved. F2 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| November 03, 2022 Filed Jan 20, 2023 23:10 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-23-000008 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President CEO and Chairman of 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,532 F1 · shares: The transaction represents a gift by the Reporting Person of 10,000 shares to a charitable donor advised fund. F2 · balance_after: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 150 | $416.42 | $62,463.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 10 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,883 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F11 · price: This transaction was executed in multiple trades at prices ranging from $416.13 to $417.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $414.99 | $41,499.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 9 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,033 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 50 | $413.51 | $20,675.50 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 8 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,133 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F10 · price: This transaction was executed in multiple trades at prices ranging from $413.14 to $414.07. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 450 | $412.27 | $185,521.50 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 7 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,183 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $411.91 to $412.41. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 405 | $411.25 | $166,556.25 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 6 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,633 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $410.79 to $411.71. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 445 | $410.00 | $182,450.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 5 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,038 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $409.67 to $410.56. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 400 | $408.89 | $163,556.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,483 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $408.53 to $409.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 150 | $407.60 | $61,140.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,883 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $407.48 to $408.055. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 405 | $407.00 | $164,835.00 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,033 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $406.37 to $407.36. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 20:29 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 445 | $405.84 | $180,598.80 |
DisclosureSEC source: 0001093557-22-000064 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,438 F1 · shares: On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $405.24 to $406.23. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:28 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 2,363 | $406.06 | $959,511.98 |
DisclosureSEC source: 0001093557-22-000053 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,883 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 00:28 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 4,473 | $406.06 | $1,816,291.62 |
DisclosureSEC source: 0001093557-22-000053 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · Chairman, CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,246 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.